146 related articles for article (PubMed ID: 37629167)
21. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract][Full Text] [Related]
22. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
[TBL] [Abstract][Full Text] [Related]
23. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
26. High VSX1 expression promotes the aggressiveness of clear cell renal cell carcinoma by transcriptionally regulating FKBP10.
Ma W; Li X; Yang L; Pan J; Chen Y; Lu Y; Dong X; Li D; Gan W
J Transl Med; 2022 Dec; 20(1):554. PubMed ID: 36463181
[TBL] [Abstract][Full Text] [Related]
27. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
28. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
[TBL] [Abstract][Full Text] [Related]
29. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
Tang F; Lu Z; He C; Zhang H; Wu W; He Z
BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
[TBL] [Abstract][Full Text] [Related]
30. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
[TBL] [Abstract][Full Text] [Related]
33. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
[TBL] [Abstract][Full Text] [Related]
34. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1-mediated translation of HIF1α in clear cell renal cell carcinoma.
Zhao P; Deng Y; Wu Y; Guo Q; Zhou L; Yang X; Wang C
FASEB J; 2021 Feb; 35(2):e21160. PubMed ID: 33150667
[TBL] [Abstract][Full Text] [Related]
36. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
[TBL] [Abstract][Full Text] [Related]
37. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
[TBL] [Abstract][Full Text] [Related]
38. Pan-cancer analysis and experiments with cell lines reveal that the slightly elevated expression of DLGAP5 is involved in clear cell renal cell carcinoma progression.
Feng Y; Li F; Yan J; Guo X; Wang F; Shi H; Du J; Zhang H; Gao Y; Li D; Yao Y; Hu W; Han J; Zhang M; Ding R; Wang X; Huang C; Zhang J
Life Sci; 2021 Dec; 287():120056. PubMed ID: 34687756
[TBL] [Abstract][Full Text] [Related]
39. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-30a-5p Inhibits the Growth of Renal Cell Carcinoma by Modulating GRP78 Expression.
Wang C; Cai L; Liu J; Wang G; Li H; Wang X; Xu W; Ren M; Feng L; Liu P; Zhang C
Cell Physiol Biochem; 2017; 43(6):2405-2419. PubMed ID: 29073630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
